相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Bowen Sun et al.
ONCOGENE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Evolving standards of care and new challenges in the management of HER2-positive breast cancer
Grace M. Choong et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Jason J. Zoeller et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
Jianliang Xu et al.
CELL COMMUNICATION AND SIGNALING (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
Konstantinos V. Floros et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Acute Myeloid Leukemia and Myelodysplastic Syndrome After Adjuvant Chemotherapy: A Population-Based Study Among Older Breast Cancer Patients
Aron S. Rosenstock et al.
CANCER (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song et al.
CLINICAL CANCER RESEARCH (2018)
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Merino et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma
Ming Yao et al.
JOURNAL OF CANCER (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
David A. Alagpulinsa et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group
Samantha C. Sodergren et al.
TARGETED ONCOLOGY (2016)
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Jungoh Ham et al.
CANCER CELL (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death
Giampaolo Morciano et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
Andres F. Cardona et al.
ONCOTARGET (2016)
Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma
Shang-Gin Wu et al.
JAMA ONCOLOGY (2016)
Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
L. Li et al.
LEUKEMIA (2015)
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Yu Xiao et al.
MOLECULAR CANCER THERAPEUTICS (2015)
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Niki Karachaliou et al.
SCIENTIFIC REPORTS (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K. Kumar et al.
BLOOD (2015)
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
G. P. Gregory et al.
LEUKEMIA (2015)
Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles
Giok S. Liem et al.
PLOS ONE (2015)
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
Aksana Kaefer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Monica M. Mita et al.
CLINICAL BREAST CANCER (2014)
Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation
H. Huang et al.
CELL DEATH & DISEASE (2014)
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
Daniel Thomas et al.
BLOOD (2013)
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
Ivana Gojo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
AMPK mediates a pro-survival autophagy downstream of PARP-1 activation in response to DNA alkylating agents
Jing Zhou et al.
FEBS LETTERS (2013)
PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis
Gregory R. Bean et al.
SCIENCE SIGNALING (2013)
BIM, PUMA, and the Achilles' Heel of Oncogene Addiction
Anne Roulston et al.
SCIENCE SIGNALING (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
Wei Fu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells
Alessandro Natoni et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
Anthony C. Faber et al.
CANCER DISCOVERY (2011)
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Andrew C. Hsieh et al.
CANCER CELL (2010)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lapatinib Side-Effect Management
Cynthia Frankel et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2010)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems
Brian R. J. Healey Bird et al.
CLINICAL CANCER RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Differential interactions between Beclin 1 and bcl-2 family members
Shlomit Erlich et al.
AUTOPHAGY (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Birth outcome in women with previously treated breast cancer - A population-based cohort study from Sweden
Kristina Dalberg et al.
PLOS MEDICINE (2006)
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update
Adam Brufsky
SEMINARS IN ONCOLOGY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The national surgical adjuvant breast and bowel project experience
RE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Transcriptional activity of P-TEFb kinase in vivo requires the C-terminal domain of RNA polymerase II
G Napolitano et al.
GENE (2000)
分享论文
